Cutler Group’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Cutler Group’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,800	Closed	-$5K	–	6333
2021 Q4	$5K	Buy	1,800 +300	+20%	+$1.91K	﹤0.01%	4262
2021 Q3	$3K	Sell	1,500 -1,100	-42%	-$7.07K	﹤0.01%	4918
2021 Q2	$5K	Buy	+2,600	New	+$21K	﹤0.01%	4512
2020 Q4	–	Sell	-1,000	Closed	-$4K	–	5702
2020 Q3	$4K	Buy	+1,000	New	+$12.6K	﹤0.01%	3748
2019 Q4	–	Sell	-4,100	Closed	-$16K	–	4812
2019 Q3	$16K	Buy	4,100 +3,100	+310%	+$31.3K	﹤0.01%	2351
2019 Q2	$4K	Buy	+1,000	New	+$5.44K	﹤0.01%	3293

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Cutler Group's PRVB Position: Q2 2023 in Review

Cutler Group sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 1,615 shares — an estimated $38K sold.

Cutler Group first reported a position in PRVB in Q2 2019 and held it in 15 quarters. The position peaked at $94K in Q4 2022. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Cutler Group reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Cutler Group sold 1,615 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $38K.
Cutler Group first reported a position in Provention Bio, Inc. Common Stock in Q2 2019 and held it in 15 quarters.
Cutler Group's Provention Bio, Inc. Common Stock position peaked at $94K in Q4 2022.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Cutler Group's 13F filing for Q2 2023, filed 18 Jul 2023.